

The board of directors of Medivir AB (publ)'s statement under Chapter 19 Section 22 of the Swedish Companies Act

The board of directors has proposed that the annual general meeting to be held on 4 May 2023 resolves to authorize the board of directors to purchase up to 970,500 C-shares. The board of directors considers, in view of what is stated below, that the resolution to acquire own shares is justifiable with respect to the requirements that the business' nature, scale and risk place on the amount of equity, as well as the need for Medivir AB (publ) to strengthen the balance sheet, liquidity and position as a whole. The board of directors has also taken into account the requirements of the group's business, scope and risk place on the group's equity requirement and need for the group to strengthen its balance sheet, liquidity and position as a whole.

Equity

The board of directors considers that the equity of Medivir AB (publ) will be of sufficient amount after the proposed acquisitions, taking into account the business' nature, scale and risk that the business is associated with and the current economic situation, historical development and forecasts for Medivir AB (publ) as well as for the market.

Need of strengthening of the balance sheet, liquidity and position as a whole

The board of directors has made a comprehensive assessment of Medivir AB (publ)'s financial position and its ability to, in the long term, fulfil its undertakings. As stated in Medivir AB (publ)'s annual report for the financial year 2022, the group's equity was SEK 192,789 thousand and the parent company's non-restricted equity of was SEK 164,318 thousand as at 31 December 2022. As at 31 December 2022, the group had assets and debts measured at fair value in accordance with chapter 4, section 14a of the Swedish Annual Accounts Act. If the assets and debts had not been measured at fair value, the group's equity would have been SEK 491 thousand higher.

The proposed acquisitions of shares do not affect Medivir AB (publ)'s ability to in due time fulfil its present and anticipated financial obligations or Medivir AB (publ)'s ability to implement planned investments.

The board of directors has also considered other known matters that may affect Medivir AB (publ)'s financial position and that have not been considered within the scope of the above mentioned. No other matter that would make the proposed acquisitions unjustifiable has been identified during such analysis.

Huddinge, April 2023
Medivir AB (publ)
The Board of Directors
